Company / Operating Income
Mineralys Therapeutics, Inc. Operating Income History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$192.4M
FY2024
5-year range
-$192.4M / -$31.5M
FY2022-FY2024
Trend
-127.3%
vs FY2023
Sector context
#142 of 204
Health Care
What the data says
At -$192M, Mineralys Therapeutics, Inc.'s operating income ranks #142 of 204 in the Health Care sector. Declined from -$31M to -$192M over the past 2 years.
Based on SEC 10-K filings.
-$192M in FY2024.
Declined from -$31M to -$192M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#142 of 204 in Health CareTop 70% of 204This company -$192.4M Sector average $107.7M
▼
-278.6% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 127.3% year-over-year.
- Ranks #142 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$192.4M | -127.3% |
| FY2023 | -$84.7M | -168.9% |
| FY2022 | -$31.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026